U.S. watchdog lifts price estimate for Bluebird, Vertex/CRISPR gene therapies to $2.1 mln

An influential U.S. drug pricing watchdog raised the price estimate of two experimental gene therapies from Vertex Pharmaceuticals /CRISPR Therapeutics and bluebird bio to as much as $2.05 mln, saying the new price can be cost effective to treat sickle cell disease.

Related Keywords

United States ,Bengaluru ,Karnataka ,India ,Bhanvi Satija ,Vertex Pharmaceuticals ,Institute For Clinical ,Reuters ,Thomson Reuters Trust Principles ,Economic Review ,David Rind ,Biomarin Pharmaceutical ,Thomson Reuters Trust ,Rhpi Biopharma ,Biodrg ,Bioph ,Blr ,Cmpny ,Gen ,Haemat ,Hea ,Heca ,Humdis ,Mevn ,Mrch ,Mrch1 ,Phar ,Phar08 ,Phmr ,Publ ,Ceeu ,Weu ,Gamers ,Us ,Europ ,Peach ,Au ,Namer ,Aunz ,Asia ,